Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer

被引:0
|
作者
Bidakhvidi, Niloefar Ahmadi [1 ,2 ]
Gevaert, Thomas [3 ]
De Schepper, Maxim [4 ]
Baldewijns, Marcella [4 ]
Havinga, Enrique [5 ]
Deckers, Wies [1 ]
Laenen, Annouschka [6 ]
Devos, Gaetan [3 ,7 ]
Giesen, Alexander [3 ,7 ]
Joniau, Steven [3 ,7 ]
Koole, Michel [1 ,2 ]
Everaerts, Wouter [7 ,8 ]
Deroose, Christophe M. [1 ,2 ]
Goffin, Karolien [1 ,2 ]
机构
[1] Univ Hosp Leuven, Nucl Med, Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Imaging & Pathol, Nucl Med & Mol Imaging, Leuven, Belgium
[3] Katholieke Univ Leuven, Dept Dev & Regenerat, Urogenital Abdominal & Plast Surg, Leuven, Belgium
[4] Univ Hosp Leuven, Pathol, Leuven, Belgium
[5] Univ Hosp Leuven, Radiol, Leuven, Belgium
[6] Interuniv Inst Biostat & Stat Bioinformat, Leuven, Belgium
[7] Univ Hosp Leuven, Urol, Leuven, Belgium
[8] Katholieke Univ Leuven, Lab Ion Channel Res, Dept Cellular & Mol Med, Leuven, Belgium
关键词
PSMA PET; PSMA immunohistochemistry; PET/MR; Parametric PET; Primary prostate cancer; IMMUNOREACTIVE SCORE; PET/CT; RECEPTORS; TISSUE; IRS;
D O I
10.1007/s00259-024-06903-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Quantification of PSMA expression via PSMA PET is well-established, however quantification of PSMA via immunohistochemistry (IHC) is not standardized. Our aim was to determine the most optimal PSMA IHC scoring system to quantify PSMA expression with PSMA PET as reference standard. Methods Primary intermediate- and high-risk prostate cancer patients received an [F-18]PSMA-1007 PET/MRI followed by radical prostatectomy. SUVmax, SUVmean and K-i of the prostate tumor was determined. Prostate tumors were stained with anti-PSMA antibodies and scored by 2 readers via 10 IHC scoring systems: histochemical score (H-score), immunoreactivity score(predominant intensity) (IRSpredominant intensity), IRS classification(predominant intensity), IRSmean intensity, IRS classification(mean intensity), Allred score, predominant expression pattern, Shannon diversity index (SDI), percentage negatively stained cells and total percentage positively stained cells. Spearman's rank correlation coefficients (rho) were calculated between PET parameters and IHC scoring systems. Interreader agreement for the IHC scoring systems was measured by the intraclass correlation coefficient (ICC). Results Fifty tumors in 46 patients were analysed. H-score had the best correlation with SUVmax (rho 0.615 p < 0.0001) and SUVmean (rho 0.570, p < 0.0001) and the second best correlation with Ki (rho 0.411, p = 0.0030). SDI had the best correlation with Ki (rho -0.440, p = 0.0014) and the second best correlation with SUVmax (rho -0.516, p = 0.0001) and SUVmean (rho -0.490, p = 0.0003). A moderate interreader agreement was observed for H-score (ICC 0.663, 95% CI 0.495-0.797) and SDI (ICC 0.546, 95% CI 0.354-0.725). Conclusion H-score had the best correlation with PSMA PET quantification and an acceptable interreader agreement. Therefore, we deem H-score the most optimal PSMA IHC scoring system.
引用
收藏
页码:766 / 778
页数:13
相关论文
共 50 条
  • [31] A Randomised Controlled Diagnostic Trial Comparing [18F]PSMA-1007 PET/CT with Conventional Imaging in Primary Staging of Prostate Cancer
    Buch-Olsen, K.
    Vilstrup, M. H.
    Hansen, S.
    Hess, S.
    Holdgaard, P. C.
    Poulsen, M. H.
    Dam, J. H.
    Madsen, S. S.
    Hildebrandt, M. G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S455 - S456
  • [32] Improved synthesis and quality control of [18F]PSMA-1007
    Fasel, Antje
    Martin, Rena
    Baumgart, Diana
    Weidlich, Sebastian
    Mueller, Marco
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S226 - S227
  • [33] Assessment of urinary bladder activity and detection of local prostate cancer lesions in [18F]PSMA-1007 PET/CT
    Krieger, K.
    Afshar-Oromieh, A.
    Rominger, A. O.
    Alberts, I. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S484 - S485
  • [34] Diagnostic accuracy of [18F]-PSMA-1007 PET/CT in biochemical recurrent prostate cancer patients - a retrospective analysis
    Mingels, C.
    Hunermund, J.
    Bohn, K. P.
    Rominger, A.
    Afshar-Oromieh, A.
    Alberts, I. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S447 - S447
  • [35] Quantitative parameters to discriminate indeterminate bone lesions on [18F]-PSMA-1007 PET/CT in prostate cancer imaging
    Sciuto, R.
    Maccora, D.
    Sanguineti, G.
    Faiella, A.
    Rea, S.
    Annovazzi, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S543 - S543
  • [36] Preclinical comparative study of [18F]AlF-PSMA-11 and [18F]PSMA-1007 in varying PSMA expressing tumors
    Piron, Sarah
    Verhoeven, Jeroen
    Courtyn, Jan
    Kersemans, Ken
    Descamps, Benedicte
    Pieters, Leen
    Vral, Anne
    Vanhove, Christian
    De Vos, Filip
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [37] Preclinical comparative study of [18F]AlF-PSMA-11 and [18F]PSMA-1007 in varying PSMA expressing tumors
    Sarah Piron
    Jeroen Verhoeven
    Jan Courtyn
    Ken Kersemans
    Benedicte Descamps
    Leen Pieters
    Anne Vral
    Christian Vanhove
    Filip De Vos
    Scientific Reports, 12
  • [38] [18F]PSMA-1007 PET/CT in the detection of neoplastic lumbosacral plexopathy as an emerging and underestimated spread of prostate cancer
    A.-L. Deleu
    N. Ahmadi Bidakhvidi
    L. Van Wynsberge
    K. Van Laere
    G. De Meerleer
    K. Goffin
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3950 - 3951
  • [39] [18F]PSMA-1007 PET/CT in the detection of neoplastic lumbosacral plexopathy as an emerging and underestimated spread of prostate cancer
    Deleu, A. -L.
    Ahmadi Bidakhvidi, N.
    Van Wynsberge, L.
    Van Laere, K.
    De Meerleer, G.
    Goffin, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (11) : 3950 - 3951
  • [40] Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology
    Bastiaan M. Privé
    Bas Israël
    Melline G. M. Schilham
    Constantijn H. J. Muselaers
    Patrik Zámecnik
    Peter F. A. Mulders
    J. Alfred Witjes
    Michiel Sedelaar
    Niven Mehra
    Fred Verzijlbergen
    Marcel J. R. Janssen
    Martin Gotthardt
    Jelle O. Barentsz
    Inge M. van Oort
    James Nagarajah
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 423 - 430